Kineta, Inc/de

TuHURA Biosciences, Inc. has successfully completed its acquisition of Kineta, Inc., integrating Kineta's novel VISTA inhibiting antibody, TBS-2025, into its late-stage immuno-oncology pipeline and unlocking a $12.5 million aggregate PIPE financing tranche.

Kineta, Inc. and TuHURA Biosciences, Inc. stockholders have overwhelmingly approved the proposed merger and related proposals, signaling a significant step towards combining their immuno-oncology development efforts.

Kineta, Inc. and TuHURA Biosciences, Inc. have amended their merger agreement, modifying the per share consideration and extending the end date to June 30, 2025, pending a minimum $20 million concurrent investment in TuHURA.

Kineta Inc. announces the resignation of Marcum LLP as its independent auditor and the engagement of CBIZ CPAs, effective March 27, 2025.

Kineta, Inc. exchanges existing warrants for common stock and a pre-funded warrant with Armistice Capital Master Fund Ltd.

Kineta, Inc. reports the termination of the GigaGen agreement and the sale of assets related to KCP506 and other intellectual property as part of its merger agreement with TuHURA Biosciences, Inc.

Kineta, Inc. reports Q1 2025 results while navigating strategic alternatives, including a proposed merger with TuHURA Biosciences, amidst substantial doubt about its ability to continue as a going concern.

Kineta Inc. released its Q3 2024 financial results, highlighting ongoing strategic review efforts and significant financial challenges, including a going concern warning.

Kineta Inc. is exploring strategic alternatives, including a potential sale or liquidation, due to substantial doubt about its ability to continue as a going concern after a private placement funding failed.

Kineta Inc. is exploring strategic alternatives, including a potential sale or liquidation, after a private placement funding fell through, raising substantial doubt about its ability to continue as a going concern.

Kineta, Inc. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and executive compensation.

Kineta, Inc. is exploring strategic alternatives, including a potential merger with TuHURA Biosciences, while facing financial challenges and doubts about its ability to continue as a going concern.

Kineta, Inc. is exploring strategic alternatives, including a potential sale or liquidation, after a significant restructuring and workforce reduction due to funding issues.

Kineta, Inc.'s Chief Scientific Officer, Thierry Guillaudeux, has reported the disposition of all his common stock and stock options in Kineta following the company's merger with TuHURA Biosciences, Inc.

A Kineta, Inc. director has reported the disposition of all direct and indirect common stock and stock options, effective June 30, 2025, as a result of the company's merger with TuHURA Biosciences, Inc.

Kineta, Inc.'s Chief Financial Officer, Keith Baker, has reported the complete disposition of his Kineta common stock and stock options as a result of the company's merger with TuHURA Biosciences, Inc.

A Kineta, Inc. director's common stock holdings were converted into TuHURA Biosciences, Inc. shares and stock options were canceled as a result of the recently completed merger between Kineta and TuHURA.

A recent SEC Form 4 filing reveals Kineta, Inc. director Marion R. Foote's disposition of common stock and cancellation of stock options as a result of the company's merger with TuHURA Biosciences, Inc.

Craig W. Philips, President and Secretary of Kineta, Inc., reported the disposition of all Kineta common stock and stock options as a result of Kineta's merger with TuHURA Biosciences, Inc., with Kineta shares converting into TuHURA common stock and certain options being canceled.

TuHURA Biosciences, Inc. has entered into a definitive agreement to acquire Kineta, Inc. in a cash and stock transaction, aiming to integrate Kineta's novel VISTA blocking immunotherapy and other assets to enhance its immuno-oncology pipeline.

TuHURA Biosciences and Kineta, Inc. have entered into a non-binding letter of intent for TuHURA to potentially acquire Kineta's KVA12123 VISTA inhibiting antibody.

Kineta, Inc. announces its 2023 Annual Meeting to be held on June 7, 2023, with stockholders voting on director elections, auditor ratification, and executive compensation.

Kineta, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 21, 2024, covering director elections, auditor ratification, and executive compensation advisory votes.

Armistice Capital and Steven Boyd have reported a significant beneficial ownership stake of 12.84% in Kineta, Inc., holding 1,823,138 shares.

Armistice Capital, LLC and Steven Boyd have reported a collective beneficial ownership of 12.84% in Kineta, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Kineta, Inc.'s common stock, held for investment purposes.